TTM2-TAME Trial

Software updates in progress, please come back at 08:30
 

All Done!

A bit more to do?    Log in


The latest from the Spiral blog . . .

Meet Jess and Emma our Project Managers

2020-09-11

 



Two smart, focussed project managers have joined Spiral recently. It’s very nice to have extra hands on deck to help deliver our Covid-19 projects.

Meet Jess and Emma our Project Managers for REMAP-CAP and for ASCOT-ADAPT.  You can read more about them over on our blog »


 
 

Follow us on Twitter

     
 

Like us on Facebook




 

About the TTM2 Study

The TTM2 trial is a phase III, multi-centre, randomized, parallel-group, clinical trial in resuscitated cardiac arrest patients admitted to the intensive care unit to investigate whether targeted temperature management (TTM) to 33°C improves survival and neurological outcome at 6 months compared to a strategy of targeting normothermia and avoiding fever above 37.7°C. More information »

About the TAME Study

The TAME trial is a phase III, multi-centre, randomised, parallel-group, clinical trial in resuscitated cardiac arrest patients admitted to the intensive care unit to determine whether targeted therapeutic mild hypercapnia (TTMH) improves neurological outcome at 6 months compared to standard care (targeted normocapnia) (TN). More information »

About the software

Spinnaker is a tailored, web based, software and database solution for managing your multi-centre clinical study including the recording of patient data, recording and alerting of events, inventory management and reporting on data collected during the course of your study. Spinnaker is user friendly, adaptable and can be delivered quickly. You can read more on the Spinnaker website or contact Audrey on spinnaker@spiral.co.nz.

 

You can get to know us a little better through our blog and social media pages accessed via the logout screen of this trial.